Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Children and adolescents with type 2 diabetes mellitus~* Insufficient glycaemic control (HbA1c \<=10.5%) despite diet and exercise and/or metformin and/or stable basal or MDI insulin~* Negative for Islet Cell Antigen and Glutamic Acid Decarboxylase autoantibodies and fasting C-peptide levels \>= 0.85 ng/ml~* BMI \> 50th percentile for age and sex~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose level \> 240 mg/dl (\> 13.3 mmol/l)~* History of acute metabolic decompensation such as diabetic ketoacidosis within 3 months before the screening visit with the exception of acute de-compensation at the time of type 2 diabetes diagnosis~* Treatment with weight reduction medications within 4 weeks before randomisation

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- empagliflozin high dose (Type: EXPERIMENTAL): Patient to receive a high dose of empagliflozin
- empagliflozin medium dose (Type: EXPERIMENTAL): Patient to receive a medium dose of empagliflozin
- empagliflozin low dose (Type: EXPERIMENTAL): Patient to receive a low dose of empagliflozin

Based on this trial design, predict the completion outcome and termination type (if applicable).